Santa Clara, Calif. - OptiMedica Corp., a global ophthalmic device company, has announced its expansion into Japan with the formation of an exclusive distribution agreement with Topcon Medical Japan Co., Ltd.
Under the terms of the agreement, Topcon Medical Japan will be the sole local distributor of OptiMedica's groundbreaking PASCAL (PAttern SCAn Laser) Photocoagulator system, a fully integrated pattern scan laser designed to treat a variety of retinal diseases including diabetic retinopathy, age-related macular degeneration and retinal vascular occlusive disease.
Unlike traditional single-spot photocoagulators, PASCAL offers a broad spectrum of pattern options that allow delivery of laser pulses in a rapid predetermined sequence, resulting in improved precision, safety and patient comfort as well as a significant reduction in treatment time.
PASCAL will be demonstrated at the Topcon Medical Japan booth at the Japanese Academy of Ophthalmology meeting in Yokohama, April 17 - 19.
"Topcon Medical Japan has a solid history of service to the ophthalmology community and has demonstrated a deep commitment to superior customer care," said Jean-Robert Strele, vice president of international business, OptiMedica.
"These values are important to OptiMedica and we look forward to entering this important partnership to serve the interests of Japanese ophthalmologists and patients."
With 10 offices across Japan, Topcon Medical Japan is a subsidiary of Topcon Corp., a world leader in the manufacturing of optical and electronic instruments.
Its product portfolio includes a broad range of premier diagnostic ophthalmic and therapeutic devices and instrumentation.
OptiMedica's PASCAL Photocoagulator system is currently distributed in major European markets by sister company Topcon Europe Medical.
"We strongly believe that adding the PASCAL Photocoagulator to our portfolio of outstanding products, which includes 3D OCT-1000 and IMAGEnet, will allow us to meet the needs of advanced medical care in the Japanese ophthalmic community," said Hiroshi Fukuzawa, director, executive officer and general manager of the Eye Care Business Unit of Topcon Medical Japan.
About Topcon Medical Japan
Topcon Medical Japan Co., Ltd. is a representative of the Japanese market for the Eye Care Business Unit of Topcon Corp.
Topcon Corp. is a world leader in the design and development of optical and electronic instruments for the medical, ophthalmic, surveying, construction and machine control businesses. Topcon Medical Japan has been a major supplier in the medical and ophthalmic instruments field for over 30 years.
About OptiMedica
OptiMedica Corp. is a Silicon Valley-based global ophthalmic device company dedicated to developing performance-driven technologies that improve patient outcomes. OptiMedica holds the exclusive license to the PASCAL (PAttern SCAn Laser) method of photocoagulation and its associated technologies, which are approved by the U.S. Food and Drug Administration for treatment of a variety of retinal conditions.
Clinical experience with PASCAL has demonstrated unmatched precision, efficiency and patient comfort. Founded in 2004, the company is headquartered in Santa Clara, Calif., with international offices in Singapore.
OptiMedica is funded by Kleiner Perkins Caufield & Byers, Alloy Ventures and DAG Ventures. For more information, please visit www.optimedica.com for OptiMedica Corp.
Nobles Communications
Laura Nobles, 310-795-0497 laura@noblescommunications.com
Under the terms of the agreement, Topcon Medical Japan will be the sole local distributor of OptiMedica's groundbreaking PASCAL (PAttern SCAn Laser) Photocoagulator system, a fully integrated pattern scan laser designed to treat a variety of retinal diseases including diabetic retinopathy, age-related macular degeneration and retinal vascular occlusive disease.
Unlike traditional single-spot photocoagulators, PASCAL offers a broad spectrum of pattern options that allow delivery of laser pulses in a rapid predetermined sequence, resulting in improved precision, safety and patient comfort as well as a significant reduction in treatment time.
PASCAL will be demonstrated at the Topcon Medical Japan booth at the Japanese Academy of Ophthalmology meeting in Yokohama, April 17 - 19.
"Topcon Medical Japan has a solid history of service to the ophthalmology community and has demonstrated a deep commitment to superior customer care," said Jean-Robert Strele, vice president of international business, OptiMedica.
"These values are important to OptiMedica and we look forward to entering this important partnership to serve the interests of Japanese ophthalmologists and patients."
With 10 offices across Japan, Topcon Medical Japan is a subsidiary of Topcon Corp., a world leader in the manufacturing of optical and electronic instruments.
Its product portfolio includes a broad range of premier diagnostic ophthalmic and therapeutic devices and instrumentation.
OptiMedica's PASCAL Photocoagulator system is currently distributed in major European markets by sister company Topcon Europe Medical.
"We strongly believe that adding the PASCAL Photocoagulator to our portfolio of outstanding products, which includes 3D OCT-1000 and IMAGEnet, will allow us to meet the needs of advanced medical care in the Japanese ophthalmic community," said Hiroshi Fukuzawa, director, executive officer and general manager of the Eye Care Business Unit of Topcon Medical Japan.
About Topcon Medical Japan
Topcon Medical Japan Co., Ltd. is a representative of the Japanese market for the Eye Care Business Unit of Topcon Corp.
Topcon Corp. is a world leader in the design and development of optical and electronic instruments for the medical, ophthalmic, surveying, construction and machine control businesses. Topcon Medical Japan has been a major supplier in the medical and ophthalmic instruments field for over 30 years.
About OptiMedica
OptiMedica Corp. is a Silicon Valley-based global ophthalmic device company dedicated to developing performance-driven technologies that improve patient outcomes. OptiMedica holds the exclusive license to the PASCAL (PAttern SCAn Laser) method of photocoagulation and its associated technologies, which are approved by the U.S. Food and Drug Administration for treatment of a variety of retinal conditions.
Clinical experience with PASCAL has demonstrated unmatched precision, efficiency and patient comfort. Founded in 2004, the company is headquartered in Santa Clara, Calif., with international offices in Singapore.
OptiMedica is funded by Kleiner Perkins Caufield & Byers, Alloy Ventures and DAG Ventures. For more information, please visit www.optimedica.com for OptiMedica Corp.
Nobles Communications
Laura Nobles, 310-795-0497 laura@noblescommunications.com
1 comment:
Inconceivable points. Sound arguments. Keep going the truly amazing work.
ophthalmic instruments
Post a Comment